Diagnostic Management Pathways for Workup of Abnormal Screening With Digital Mammography Versus Digital Breast Tomosynthesis

数字乳腺X线摄影与数字乳腺断层合成在异常筛查诊断管理路径中的比较

阅读:1

Abstract

PURPOSE: Our objective was to assess the transition from digital mammography (DM) to digital breast tomosynthesis (DBT) screening, the authors compared diagnostic workup type and frequency, workup pathways, and time to resolution of abnormal screening between DBT and DM. METHODS: This cohort study included screening examinations with an abnormal results from 2011 to 2020 at 107 facilities across six Breast Cancer Surveillance Consortium registries. Diagnostic workup included diagnostic DM, diagnostic DBT, ultrasound, MRI, and biopsy within 90 days of the abnormal result on screening mammography. Workup modalities and number of workup procedures were compared using differences in proportion and 95% confidence intervals (CIs). Time to diagnostic resolution between DBT and DM was compared using a log-rank test. RESULTS: Among 77,123 DBT and 197,589 abnormal DM screening examinations with abnormal results, the number of imaging modalities in the diagnostic pathway was similar. The first workup procedure was more often ultrasound after abnormal results on DBT compared with DM (21.1% versus 4.7%). Biopsy rates were higher for DBT versus DM (16.2% versus 14.0%; difference in proportions = 2.27; 95% CI, 1.97-2.58) with biopsies after DM versus DBT more likely surgical versus fine-needle aspiration or core (5.8% versus 3.2%; difference in proportions = 2.6; 95% CI, 2.19-3.01), resulting in a rate of excision biopsy per 1,000 screens with abnormal findings of 5.1 for DBT and 8.0 for DM. Time to diagnostic resolution was similar (median, 10 days). CONCLUSIONS: This study revealed differences in the type of diagnostic workup pathways after abnormal results on screening DBT versus DM. Although the biopsy rate was higher after abnormal results on DBT, the biopsy type may be more invasive (surgical excision) after abnormal results on DM.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。